The latest closing stock price for Inhibikase Therapeutics as of September 18, 2024 is 1.17.
An investor who bought $1,000 worth of Inhibikase Therapeutics stock at the IPO in 2020 would have $-882 today, roughly -1 times their original investment - a -41.37% compound annual growth rate over 4 years.
The all-time high Inhibikase Therapeutics stock closing price was 9.90 on December 23, 2020.
The Inhibikase Therapeutics 52-week high stock price is 3.82, which is 226.5% above the current share price.
The Inhibikase Therapeutics 52-week low stock price is 0.79, which is 32.5% below the current share price.
The average Inhibikase Therapeutics stock price for the last 52 weeks is 1.58.
An investor who bought $1,000 worth of Inhibikase Therapeutics stock at the IPO in 2020 would have $-882 today, roughly -1 times their original investment - a -41.37% compound annual growth rate over 4 years.
The all-time high Inhibikase Therapeutics stock closing price was 9.90 on December 23, 2020.
The Inhibikase Therapeutics 52-week high stock price is 3.82, which is 226.5% above the current share price.
The Inhibikase Therapeutics 52-week low stock price is 0.79, which is 32.5% below the current share price.
The average Inhibikase Therapeutics stock price for the last 52 weeks is 1.58.